{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:42:13Z","timestamp":1794642133572,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0771-0","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T07:24:11Z","timestamp":1518074651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-1306","authenticated-orcid":false,"given":"Rossella","family":"Parini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cavarzere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Concolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Della Casa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Fiumara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Menni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Pagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Sacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Taurisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC-H, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human \u03b1-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149:89\u201397.","journal-title":"J Pediatr"},{"key":"771_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99\u2013109.","journal-title":"Neurology"},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"P Kishnani","year":"2009","unstructured":"Kishnani P, Corzo D, Leslie N, Gruskin D, van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediat Res. 2009;66:329\u201335.","journal-title":"Pediat Res"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","volume":"11","author":"M Nicolino","year":"2009","unstructured":"Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11:210\u20139.","journal-title":"Genet Med"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26\u201333.","journal-title":"Mol Genet Metab"},{"key":"771_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease. N Engl J Med. 2009;360:194\u20135.","journal-title":"N Engl J Med"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/0883073813485819","volume":"29","author":"F Deodato","year":"2014","unstructured":"Deodato F, Ginocchio VM, Onofri A, Grutter G, Germani A, Dionisi-Vici C. Immune tolerance induced using plasma exchange and rituximab in an infantile Pompe disease patient. J Child Neurol. 2014;29:850\u20134.","journal-title":"J Child Neurol"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","volume":"14","author":"YH Messinger","year":"2012","unstructured":"Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14:135\u201342.","journal-title":"Genet Med"},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","volume":"163","author":"ME Elder","year":"2013","unstructured":"Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, et al. B-cell Depletion and Immunomodulation Prior to Initiation of Enzyme Replacement Therapy Blocks the Immune Response to Acid Alpha Glucosidase in Infantile Onset Pompe Disease. J Pediatr. 2013;163:847\u201354.e1.","journal-title":"J Pediatr"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","volume":"166","author":"Y-H Chien","year":"2015","unstructured":"Chien Y-H, Lee N-C, Chen C-A, Tsai F-J, Tsai W-H, Shieh J-Y, et al. Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth. J Pediatr. 2015;166:985\u201391. (e981\u2013982)","journal-title":"J Pediatr"},{"key":"771_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","volume":"169","author":"CF Yang","year":"2016","unstructured":"Yang CF, Yang CC, Liao HC, Huang L-Y, Chiang C-C, Ho H-C, et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. 2016;169:174\u201380.","journal-title":"J Pediatr"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","volume":"33","author":"A Chakrapani","year":"2010","unstructured":"Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis. 2010;33:747\u201350.","journal-title":"J Inherit Metab Dis"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/8904_2014_392","volume":"20","author":"A Hahn","year":"2015","unstructured":"Hahn A, Praetorius S, Karabul N, Die\u00dfel J, Schmidt D, Motz R, et al. Outcome of patients with classical infantile Pompe disease receiving enzyme replacement therapy in Germany. JIMD Rep. 2015;20:65\u201375.","journal-title":"JIMD Rep"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","volume":"38","author":"CM van Gelder","year":"2015","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38:305\u201314.","journal-title":"J Inherit Metab Dis"},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","volume":"39","author":"A Broomfield","year":"2016","unstructured":"Broomfield A, Fletcher J, Davison J, Finnegan N, Fenton M, Chikermane A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016;39:261\u201371.","journal-title":"J Inherit Metab Dis"},{"key":"771_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.nmd.2014.12.004","volume":"25","author":"LE Case","year":"2015","unstructured":"Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord. 2015;25:321\u201332.","journal-title":"Neuromuscul Disord"},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","volume":"39","author":"CM van Gelder","year":"2016","unstructured":"van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek NAME, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39:383\u201390.","journal-title":"J Inherit Metab Dis"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1203\/01.pdr.0000233014.84318.4e","volume":"60","author":"Y-H Chien","year":"2006","unstructured":"Chien Y-H, Lee N-C, Peng S-F, Hwu W-L. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res. 2006;60:349\u201352.","journal-title":"Pediatr Res"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","volume":"78","author":"BJ Ebbink","year":"2012","unstructured":"Ebbink BJ, Aarsen FK, van Gelder CM, van den Hout JMP, Weisglas-Kuperus N, Jaeken J, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology. 2012;78:1512\u20138.","journal-title":"Neurology"},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.0000000000002523","volume":"86","author":"BJ Ebbink","year":"2016","unstructured":"Ebbink BJ, Poelman E, Plug I, Lequin MH, van Doorn PA, Aarsen FK, et al. Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge. Neurology. 2016;86:1260\u20131.","journal-title":"Neurology"},{"key":"771_CR21","doi-asserted-by":"crossref","unstructured":"McIntosh PT, Hobson-Webb LD, Kazi ZB, Prater SN, Banugaria SG, Austin S, et al. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab. 2018;123:85\u201391.","DOI":"10.1016\/j.ymgme.2017.10.005"},{"key":"771_CR22","doi-asserted-by":"crossref","unstructured":"Andersen PK, Borgan \u00d8, Gill RD, Keiding N. Statistical models based on counting processes. New York, NY: Springer US; 1993.","DOI":"10.1007\/978-1-4612-4348-9"},{"key":"771_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","volume":"160C","author":"DS Bali","year":"2012","unstructured":"Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet. 2012;160C:40\u20139.","journal-title":"Am J Med Genet"},{"key":"771_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nbd.2003.12.018","volume":"16","author":"JHJ Kamphoven","year":"2004","unstructured":"Kamphoven JHJ, de Ruiter MM, Winkel LPF, Van den Hout HMP, Bijman J, De Zeeuw CI, et al. Hearing loss in infantile Pompe\u2019s disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis. 2004;16:14\u201320.","journal-title":"Neurobiol Dis"},{"key":"771_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10545-010-9144-0","volume":"33","author":"CI van Capelle","year":"2010","unstructured":"van Capelle CI, Goedegebure A, Homans NC, Hoeve HLJ, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inherit Metab Dis. 2010;33:597\u2013602.","journal-title":"J Inherit Metab Dis"},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gim.2012.44","volume":"14","author":"SN Prater","year":"2012","unstructured":"Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14:800\u201310.","journal-title":"Genet Med"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng Y-K, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13:729\u201336.","journal-title":"Genet Med"},{"key":"771_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1172\/JCI115025","volume":"87","author":"AT Van der Ploeg","year":"1991","unstructured":"Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest. 1991;87:513\u20138.","journal-title":"J Clin Invest"},{"key":"771_CR29","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","volume":"288","author":"JA Maga","year":"2013","unstructured":"Maga JA, Zhou J, Kambampati R, Peng S, Wang X, Bohnsack RN, et al. Glycosylation-independent lysosomal targeting of acid -glucosidase enhances muscle glycogen clearance in Pompe mice. J Biol Chem. 2013;288:1428\u201338.","journal-title":"J Biol Chem"},{"key":"771_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","volume":"94","author":"AJ McVie-Wylie","year":"2008","unstructured":"McVie-Wylie AJ, Lee KL, Qiu H, Jin X, Do H, Gotschall R, et al. Biochemical and pharmacological characterization of different recombinant acid \u03b1-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab. 2008;94:448\u201355.","journal-title":"Mol Genet Metab"},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-016-0446-7","volume":"11","author":"SS Peng","year":"2016","unstructured":"Peng SS, Hwu WL, Lee NC, Tsai FJ, Tsai WH, Chien YH. Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study. Orphanet J Rare Dis. 2016;11:63.","journal-title":"Orphanet J Rare Dis"},{"key":"771_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgmr.2016.11.001","volume":"9","author":"T Matsuoka","year":"2016","unstructured":"Matsuoka T, Miwa Y, Tajika M, Sawada M, Fujimaki K, Soga T, et al. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state. Mol Genet Metab Rep. 2016;9:98\u2013105.","journal-title":"Mol Genet Metab Rep"},{"key":"771_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ymgmr.2017.05.005","volume":"12","author":"A Sch\u00e4nzer","year":"2017","unstructured":"Sch\u00e4nzer A, Giese K, Viergutz L, Hahn A. Letter to the editors: concerning \"divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state\" by Takashi et al. and letter to the editors by Ortolano et al. Mol Genet Metab Rep. 2017;12:33\u20134.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T19:31:32Z","timestamp":1549567892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0771-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0771-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,8]]},"assertion":[{"value":"30 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study follows the Helsinki Declaration\u2019s principles and was carried out from retrospective review of routine clinical data: formal ethics review was therefore not requested.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients or their parents\/guardians gave a written consent to publication of their anonymized clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"\u2022 RP received travel grants for scientific meetings and honoraria for speaking engagements or consultations from Shire\u00a0International, Sanofi Genzyme, BioMarin and SOBI. She is involved in Advisory Boards on Lysosomal diseases upon request of BioMarin, Shire International\u00a0and Sanofi Genzyme. She is or has recently been involved as PI in clinical trials with BioMarin, Shire\u00a0Inernational and Synageva.\u2022 BB received honoraria for speaking engagement and post-doc grants from Sanofi Genzyme, Actelion and Shire international.\u2022 AB received honoraria for speaking engagement from Sanofi Genzyme and Actelion\u2022 DC received travel grants for scientific meetings from Shire\u00a0International and Sanofi Genzyme, and honoraria for speaking engagements from Shire.\u2022 MAD received travel grants for scientific meetings and honoraria for speaking engagements from Shire\u00a0International, Sanofi Genzyme and BioMarin.\u2022 AF received travel grants for scientific meetings by Sanofi Genzyme, Bio Marin, Shire\u00a0International and Actelion. She is involved in Advisory Boards on Lysosomal diseases upon request of BioMarin and Sanofi Genzyme.\u2022 SG received travel grants for scientific meetings and honoraria for speaking engagement from Sanofi Genzyme, SOBI and Shire international. She is involved as PI in clinical studies with Shire and Alexion and as SI in clinical studies with BioMarin, Shire International and Sanofi Genzyme.\u2022 MaS received travel grants for scientific meetings and honoraria for speaking engagement from Sanofi Genzyme, and Shire International.\u2022 MDR received travel grants for scientific meetings and honoraria for speaking engagements or consultation from Sanofi Genzyme\u2022 FM, RDC, FD, VP and RT received travel grants for scientific meetings from Sanofi Genzyme and Shire\u00a0International.\u2022 PDL, AC, PC, MiS, MGV declare competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"32"}}